Loading...

Interactive dashboard visualizing Health-Related Quality of Life (HRQOL) outcomes from the MONALEESA-3 study comparing Ribociclib + Fulvestrant vs. Placebo + Fulvestrant.

Study Design & Arms

Baseline Scores (Mean ± SD)

Comparison of baseline Global HRQOL and Pain scores between arms. Higher scores indicate better QOL for Global Health, but worse symptoms for Pain.

Time to Deterioration (Hazard Ratios)

Hazard Ratios (HR) for time to definitive deterioration (TTD) ≥10%. HR < 1.0 favors Ribociclib + Fulvestrant.

Change from Baseline (Pain Scores)

Least squares mean change from baseline at 8 weeks. Negative values indicate reduction in pain.

Metric Overview Heatmap

Overview of all extracted quantitative metrics. Values are normalized for visualization where applicable.

Data Provenance Map

Visualizing the source locations of the extracted data points within the document.

Appendix: Raw Data